Zacks Investment Research downgraded shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a research report released on Friday morning.
According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
Several other equities analysts also recently issued reports on SVRA. HC Wainwright reaffirmed a buy rating on shares of Savara in a report on Thursday, November 8th. ValuEngine downgraded shares of Savara from a hold rating to a sell rating in a report on Wednesday, November 21st. Finally, BidaskClub downgraded shares of Savara from a hold rating to a sell rating in a report on Friday, November 30th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $24.75.
SVRA opened at $7.77 on Friday. The company has a current ratio of 10.23, a quick ratio of 10.23 and a debt-to-equity ratio of 0.10. The firm has a market cap of $272.95 million, a price-to-earnings ratio of -4.41 and a beta of 0.85. Savara has a 52-week low of $6.21 and a 52-week high of $14.06.
In related news, CEO Robert N. Neville acquired 23,517 shares of the firm’s stock in a transaction on Friday, December 21st. The shares were acquired at an average cost of $6.38 per share, with a total value of $150,038.46. Following the completion of the acquisition, the chief executive officer now directly owns 498,028 shares in the company, valued at approximately $3,177,418.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.10% of the company’s stock.
Large investors have recently bought and sold shares of the company. Alps Advisors Inc. lifted its stake in shares of Savara by 30.7% in the fourth quarter. Alps Advisors Inc. now owns 81,180 shares of the company’s stock worth $615,000 after buying an additional 19,077 shares in the last quarter. Sofinnova Ventures Inc lifted its stake in shares of Savara by 172.0% in the third quarter. Sofinnova Ventures Inc now owns 698,225 shares of the company’s stock worth $7,793,000 after buying an additional 441,533 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Savara by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 20,243 shares of the company’s stock worth $226,000 after buying an additional 7,196 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Savara by 8.2% in the third quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock worth $24,220,000 after buying an additional 164,056 shares in the last quarter. Finally, Nexthera Capital LP purchased a new position in Savara during the third quarter worth about $1,089,000. 51.61% of the stock is currently owned by hedge funds and other institutional investors.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.